{"id":60591,"date":"2026-03-23T16:12:07","date_gmt":"2026-03-23T08:12:07","guid":{"rendered":"https:\/\/flcube.com\/?p=60591"},"modified":"2026-03-23T16:12:08","modified_gmt":"2026-03-23T08:12:08","slug":"henlius-biotech-reports-2025-revenue-growth-16-5-ex-china-business-doubles-as-global-expansion-accelerates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60591","title":{"rendered":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced <strong>strong 2025 annual results<\/strong>, with <strong>revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion<\/strong> and <strong>net profit of RMB 827 million<\/strong>, driven by <strong>17.0% global product revenue growth<\/strong> and <strong>doubling of ex\u2011China business<\/strong> \u2013 validating the company&#8217;s <strong>international commercialization strategy<\/strong> across <strong>60 countries and regions<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-fy2025\">Financial Performance \u2013 FY2025<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2025<\/th><th>YoY Change<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 6.6666 billion<\/td><td><strong>+16.5%<\/strong><\/td><td>Sustained double\u2011digit growth amid biosimilar competition<\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>RMB 0.8270 billion<\/td><td>Profitable<\/td><td>Margin expansion from licensing and ex\u2011China mix<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 2.4919 billion<\/td><td><strong>+35.4%<\/strong><\/td><td>Aggressive pipeline advancement; 27 INDs secured<\/td><\/tr><tr><td><strong>Global Product Revenue<\/strong><\/td><td>RMB 5.7746 billion<\/td><td><strong>+17.0%<\/strong><\/td><td>International commercialization traction<\/td><\/tr><tr><td><strong>Ex\u2011China Product Revenue<\/strong><\/td><td>&gt;RMB 200 million<\/td><td><strong>Doubled YoY<\/strong><\/td><td>Critical inflection point for global business<\/td><\/tr><tr><td><strong>Ex\u2011China Product Profit<\/strong><\/td><td>RMB 93.9 million<\/td><td>Profitable<\/td><td>Validation of ex\u2011China unit economics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-amp-commercial-footprint\">Global Regulatory &amp; Commercial Footprint<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Achievement<\/th><th>Market Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Approvals<\/strong><\/td><td><strong>10 products<\/strong> in <strong>60 countries\/regions<\/strong><\/td><td>Established global biosimilar presence<\/td><\/tr><tr><td><strong>China Approvals<\/strong><\/td><td><strong>7 products<\/strong><\/td><td>Dominant domestic market position<\/td><\/tr><tr><td><strong>US FDA Approvals<\/strong><\/td><td><strong>4 products<\/strong><\/td><td>Premium market access; HERCESSI (trastuzumab) launch<\/td><\/tr><tr><td><strong>European Commission<\/strong><\/td><td><strong>4 products<\/strong><\/td><td>Zercepac, Hetronifly established in EU<\/td><\/tr><tr><td><strong>Patients Benefited<\/strong><\/td><td><strong>&gt;1 million globally<\/strong><\/td><td>Commercial scale validation<\/td><\/tr><tr><td><strong>2025 New Approvals<\/strong><\/td><td><strong>28 marketing approvals<\/strong> + <strong>27 INDs<\/strong><\/td><td>Accelerated global pipeline execution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-products-driving-growth\">Core Products Driving Growth<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Global Brand Names<\/th><th>Therapeutic Area<\/th><th>Ex\u2011China Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>Serplulimab<\/strong><\/td><td>Hetronifly (Europe)<\/td><td>PD\u20111 inhibitor (SCLC, etc.)<\/td><td>Abbott, Eisai, Lotus partnerships<\/td><\/tr><tr><td><strong>Trastuzumab<\/strong><\/td><td>HERCESSI (US), Zercepac (Europe)<\/td><td>HER2+ breast\/gastric cancer<\/td><td>US launch momentum; EU market leadership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnerships-2025-expansion\">Strategic Partnerships \u2013 2025 Expansion<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partner<\/th><th>Product\/Asset<\/th><th>Partnership Type<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Abbott<\/strong><\/td><td>Serplulimab<\/td><td>Commercialization rights<\/td><td>Emerging market access; diagnostic synergy<\/td><\/tr><tr><td><strong>Eisai<\/strong><\/td><td>Serplulimab<\/td><td>Co\u2011development\/marketing<\/td><td>Oncology expertise; Japan market potential<\/td><\/tr><tr><td><strong>Lotus<\/strong><\/td><td>Serplulimab<\/td><td>Regional rights<\/td><td>Southeast Asia expansion<\/td><\/tr><tr><td><strong>Dr. Reddy&#8217;s<\/strong><\/td><td>HLX15 (daratumumab biosimilar)<\/td><td>Licensing<\/td><td>India + emerging markets manufacturing\/commercial<\/td><\/tr><tr><td><strong>Sandoz<\/strong><\/td><td>HLX13 (ipilimumab biosimilar)<\/td><td>Licensing<\/td><td>Global immunology franchise access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biosimilar Market Leadership:<\/strong> Henlius&#8217;s <strong>16.5% revenue growth<\/strong> outpaces industry average (~10%) driven by <strong>innovator\u2011quality manufacturing<\/strong> and <strong>aggressive pricing<\/strong>; trastuzumab (HERCESSI\/Zercepac) and serplulimab (PD\u20111) franchises defend against domestic competition (Bio\u2011Thera, Cinda Biologics) through <strong>global regulatory credibility<\/strong> (FDA\/EMA approvals).<\/li>\n\n\n\n<li><strong>Ex\u2011China Inflection:<\/strong> <strong>Doubling of ex\u2011China revenue<\/strong> to >RMB 200 million with <strong>RMB 93.9 million profit<\/strong> demonstrates <strong>sustainable international unit economics<\/strong> \u2013 critical for valuation re\u2011rating from &#8220;China\u2011only biosimilar&#8221; to &#8220;global biotech platform&#8221;; US HERCESSI launch (2024\u20112025) and EU Zercepac market share gains drive 2026\u20112027 trajectory.<\/li>\n\n\n\n<li><strong>R&amp;D Productivity:<\/strong> <strong>RMB 2.5 billion R&amp;D investment<\/strong> (+35.4%) yields <strong>27 INDs<\/strong> \u2013 industry\u2011leading pace for China biotech; pipeline includes <strong>HLX15 (daratumumab)<\/strong>, <strong>HLX13 (ipilimumab)<\/strong>, <strong>novel ADCs<\/strong>, and <strong>bispecific antibodies<\/strong>; Dr. Reddy&#8217;s and Sandoz partnerships validate <strong>early\u2011stage asset attractiveness<\/strong> for global licensing.<\/li>\n\n\n\n<li><strong>Partnership\u2011Driven Growth:<\/strong> 2025 collaborations with <strong>Abbott, Eisai, Lotus, Dr. Reddy&#8217;s, Sandoz<\/strong> transform Henlius from <strong>product\u2011centric<\/strong> to <strong>platform\u2011centric<\/strong> business model; licensing revenue streams (milestones, royalties) reduce dependency on product sales volatility; estimated <strong>RMB500\u2011800 million<\/strong> annual licensing revenue potential by 2027\u20112028.<\/li>\n\n\n\n<li><strong>2026 Strategic Priorities:<\/strong> US HERCESSI market share expansion (target 15\u201120% of trastuzumab biosimilar volume); EU Hetronifly (serplulimab) launch completion; HLX15\/HLX13 Phase III execution; novel biologics (ADCs, bispecifics) IND acceleration; potential <strong>secondary listing<\/strong> (US or EU) to access global capital markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue growth expectations, partnership performance, and global expansion timelines for Henlius Biotech. Actual results may differ due to competitive pricing pressures, regulatory approval delays in key markets, and manufacturing scale\u2011up challenges for novel biologics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000990_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032000990_c.\"><\/object><a id=\"wp-block-file--media-dc557984-f406-4acb-a840-1e757f66fadc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000990_c.pdf\">2026032000990_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000990_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dc557984-f406-4acb-a840-1e757f66fadc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,270,862],"class_list":["post-60591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company&#039;s international commercialization strategy across 60 countries and regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60591\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company&#039;s international commercialization strategy across 60 countries and regions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60591\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T08:12:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T08:12:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates\",\"datePublished\":\"2026-03-23T08:12:07+00:00\",\"dateModified\":\"2026-03-23T08:12:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2306.webp\",\"keywords\":[\"Finanical Reports\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60591#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60591\",\"name\":\"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2306.webp\",\"datePublished\":\"2026-03-23T08:12:07+00:00\",\"dateModified\":\"2026-03-23T08:12:08+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company's international commercialization strategy across 60 countries and regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60591\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60591#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company's international commercialization strategy across 60 countries and regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60591","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company's international commercialization strategy across 60 countries and regions.","og_url":"https:\/\/flcube.com\/?p=60591","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T08:12:07+00:00","article_modified_time":"2026-03-23T08:12:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60591#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60591"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates","datePublished":"2026-03-23T08:12:07+00:00","dateModified":"2026-03-23T08:12:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60591"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60591#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","keywords":["Finanical Reports","Henlius Biotech","HKG: 2696"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60591#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60591","url":"https:\/\/flcube.com\/?p=60591","name":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60591#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60591#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","datePublished":"2026-03-23T08:12:07+00:00","dateModified":"2026-03-23T08:12:08+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced strong 2025 annual results, with revenue rising 16.5% year\u2011on\u2011year to RMB 6.67 billion and net profit of RMB 827 million, driven by 17.0% global product revenue growth and doubling of ex\u2011China business \u2013 validating the company's international commercialization strategy across 60 countries and regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60591#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60591"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60591#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","width":1080,"height":608,"caption":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60591#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Reports 2025 Revenue Growth 16.5% \u2013 Ex\u2011China Business Doubles as Global Expansion Accelerates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60591"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60591\/revisions"}],"predecessor-version":[{"id":60595,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60591\/revisions\/60595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60593"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}